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remain	 extremely	 high.	 It	 is	 therefore,	 of	 paramount	 importance,	 any	
contributions	to	the	field.		
The	 prevalence	 of	 atherosclerosis	 is	 ubiquitous	 in	 today’s	 society	 and,	
again,	 any	 measures	 or	 interventions	 to	 prevent	 or	 reverse	 its	 development,	





Phospholipase	 A2	 enzymes	 are	 a	 diverse	 class	 of	 esterases	 able	 to	
recognize	 and	 catalyze	 the	 hydrolysis	 of	 the	 sn-2	 ester	 bond	 of	
glycerophospholipids	 yielding	 nonesterified	 fatty	 acids	 (NEFAs),	 such	 as	
arachidonic	 acid;	 and	 lysophospholipids.	 This	 superfamily	 of	 enzymes	 is	 then	
divided	 into	 six	 families	 based	 on	 their	 structure,	 catalytic	 mechanism,	
localization	 and	 evolutionary	 relationships.	 These	 include	 1)	 intracellular	
cytosolic	 Ca2+-dependent,	 2)	 intracellular	 cytosolic	 Ca2+-independent,	 3)	
secretory	phospholipase	A2	(sPLA2),	4)	lysosomal	phospholipase	A2,	5)	adipose	
specific	phospholipase	A2,	and	6)	Lipoprotein-associated	phospholipase	A2	(Lp-





AH)	due	 to	 the	 fact	 that	 it	was	discovered	because	of	 its	ability	 to	 catalyze	 the	
hydrolysis	of	PAF;		or	as	phospholipase	A2	group	7	(PLA2G7,	because	of	the	gene	
in	 which	 it	 is	 encoded).	 It	 is	 thought	 to	 have	 considerable	 physiologic	 and	
pathophysiologic	 roles	 being	 an	 active	 participant	 and	 mediator	 in	 states	 of	
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oxidative	 stress,	 inflammation	 and	 atherosclerosis	 plaque	 development	 and	
progression.	 It	 is,	 therefore,	 not	 surprising	 that	 substantial	 investigations	have	
been	 performed	 in	 the	 last	 years	 exploring	 the	 functions,	 involved	 metabolic	




Lp-PLA2	 is	 an	 extracellular	 Ca2+-independent	 45	 KDa	 secreted	 enzyme	
formed	 by	 441	 amino	 acids,	 that	 circulates	 in	 plasma	 in	 the	 active	 form.	 It	 is	
encoded	in	the	PLA2G7	gene	located	on	chromosome	6p12-21.1.	Chemically,	by	
possessing	a	serine/aspartate/histidine	catalytic	triad	(or	Gly-X-Ser-X-Gly	motif),	
the	enzyme	has	more	 in	 common	with	neutral	 lipases	 and	esterases	 than	with	
other	members	of	 the	PLA2	 superfamily	 (which	have	 a	 serine/aspartate	dyad)	
(Cao	et	al.,	2011).	It	has	a	canonical	tertiary	fold	arrangement	with	binding	sites	
for	 low-	 and	 high-density	 lipoproteins	 (LDL	 and	 HDL,	 respectively).	






glycerol	 backbone.	 Due	 to	 this	 unique	 substrate	 specificity,	 the	 enzyme	 can	
circulate	 freely	 in	 the	 plasma	 in	 the	 active	 form	 without	 hydrolyzing	 native	
cellular	phospholipids	(it	only	hydrolyzes	phospholipids	where	the	fatty	acid	on	
the	 sn-2	 position	 became	 shortened	 or	 oxidized).	 Oxidized	 phospholipids	 are	
thought	 to	 induce	macrophage	 recruitment	 and	 to	 contribute	 to	 the	 initiation	
and	progression	of	 chronic	 inflammation	 characteristic	 for	 atherosclerosis.	 Lp-
PLA2	 might	 have	 a	 protective	 function	 in	 this	 setting	 by	 hydrolyzing	 these	
bioactive,	 proinflammatory,	 oxidatively	 fragmented	 phospholipids	 produced	
during	the	oxidation	of	LDL.		
On	 the	 other	 hand,	 as	 the	 burden	 of	 oxidized	 phospholipids	 increases	
with	disease	progression,	 there	 is	an	 increased	expression	of	proinflammatory,	




Lysophosphatidylcholine,	 through	 its	 action	 on	 the	 G-protein-coupled	
receptor	 G2A,	 modulates	 endothelial	 activation,	 suppresses	 nitric	 oxide	
generation,	inhibits	cell	migration	and	proliferation,	and	inhibits	the	phagocytic	
clearance	 of	 apoptotic	 cells	 (Mallat,	 Lambeau	 and	Tedgui,	 2010).	 These	 effects	
may	 contribute	 to	 the	 initiation	 and	 progression	 of	 atherosclerosis.	 The	
concentration	 of	 lysophosphatidylcholine	 in	 the	 plasma	 of	 healthy	 individuals	
usually	 ranges	 from	 200	 to	 400	 μmol/l.	 A	 scheme	 depicting	 pathophysiologic	
effects	 of	 oxidized	 phosphatidylcholine	 is	 shown	 in	 Figure	 1.	 In	 summary,	 Lp-
PLA2	 seems	 to	 be	 a	 promoter	 in	 the	 development	 and	 progression	 of	










to	 endothelial	 cells,	 enhance	 cyclooxygenase-2	 expression,	 increase	 the	
production	of	tumor	necrosis	factor,	and	others	(Oestvang	and	Johansen,	2006).	
These	 fatty	 acids,	 however,	 are	 structurally	 different	 from	 those	 generated	 by	
Lp-PLA2,	which	yields	oxidized	short	to	medium	chain	fatty	acids.	
Short-chain	 oxidized	 NEFAs	 may	 act	 as	 endogenous	 ligands	 of	 nuclear	





to	 properly	 function	 and	 hydrolyzes	 a	wide	 range	 of	 phospholipids	 substrates	
depending	 on	 the	 enzyme	 isoform.	 Like	 Lp-PLA2,	 sPLA2	 may	 exert	
proatherogenic	effects	in	the	arterial	wall	(Webb,	2005).	Phospholipid	hydrolysis	







Note	 that,	 in	 contrast	 to	 Lp-PLA2,	 sPLA2	 hydrolyses	 non-oxidized	
phospholipids	 contained	 in	 non-oxidized	 LDL	 particles.	 Besides	 this	 function,	
sPLA2	has	been	 recently	 shown	 to	play	an	 important	 role	 in	allergic	 reactions,	
being	 a	 regulator	of	mast	 cells	maturation	 (Murakami	 and	Taketomi,	 2015),	 in	
the	 local	 mediation	 of	 lipid	 metabolism	 in	 response	 a	 specific	
microenvironmental	 cues	 (Sato	 et	 al.,	 2014),	 and	 in	 the	 immune	 defense,	 by	
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hydrolyzing	 phosphatidylethanolamine	 and	 phosphatidylglycerol,	 major	








lipoprotein	 (VLDL).	 It	 has	 greater	 affinity	 for	 the	 smallest,	 densest,	 most	
electronegative	 LDL	 particles,	 probably	 because	 of	 the	 conformation	 apoB100	
adopts	 in	 these	 particles	 (which	 is	 distinct	 from	 that	 seen	 in	 larger	 LDL),	
facilitating	 Lp-PLA2	 binding	 (Stafforini	 et	 al.,	 1999).	 However,	 only	 a	 small	
fraction	 of	 circulating	 LDL	 particles	 has	 Lp-PLA2	 attached	 to	 it	 (about	 1%),	
which	means	that	most	of	the	LDL	particles	do	not	contain	this	enzyme	at	all.	The	
binding	 site	 on	 Lp-PLA2	 molecule	 differs	 according	 whether	 the	 carrier	
lipoprotein	 is	 LDL	 or	 HDL.	 Lp-PLA2	 bound	 to	 HDL	 has	 a	much	 lower	 specific	
activity	than	that	bound	to	LDL.	The	LDL/HDL	ratio	for	the	enzyme	may	depend	
on	the	extent	of	its	glycosylation.	
From	all	 circulating	 lipoproteins	 it	 is	 estimated	 that	only	 approximately	
0.1%	are	laden	with	Lp-PLA2.	It	also	binds	to	the	apoB-containing	Lp(a),	which	
transports	 oxidized	 phospholipids.	 When	 Lp-PLA2	 acts	 within	 its	 normal	
physiological	 levels	 it	 may	 have	 beneficial	 effects	 because	 it	 hydrolysis	 these	
oxidized	phospholipids,	decreasing	their	proinflammatory	potential.		
		 In	 other	 mammalian	 species,	 because	 of	 different	 lipoprotein	 profiles	
when	compared	to	humans,	Lp-PLA2	may	be	exclusively	bound	to	HDL.	This	 is	
true	for	guinea	pigs,	rats	and	mice,	and	can	have	significant	repercussions	when	
studying	 the	 enzyme	 function.	 In	 this	 case	 Lp-PLA2	 works	 solely	 in	 an	
antiatherogenic	manner.	
Because	of	 this	dual	role	 it	was	proposed	that	 the	 type	of	 lipoprotein	 to	




Furthermore,	 the	homeostasis	of	Lp-PLA2	 is	 influenced	by	 the	ratio	and	
distribution	 of	 the	 different	 lipoprotein	 classes.	 In	 primary	
hypercholesterolemia,	 LDL-bound	 Lp-PLA2	 increases	 with	 the	 severity	 of	 the	
disease.	In	homozygous	familial	hypercholesterolemia	there	are	very	high	levels	
of	 LDL-bound	 Lp-PLA2.	 Other	 types	 of	 mixed	 dyslipidemias,	 such	 as	 seen	 in	
diabetes	mellitus,	may	also	alter	the	function	and	distribution	of	Lp-PLA2.	
In	summary,	LDL	particles	provide	a	circulating	reservoir	for	the	Lp-PLA2	
enzyme,	 which	 remains	 inactive	 until	 LDL	 undergoes	 oxidation.	 After	 LDL	
oxidation	 within	 the	 arterial	 wall,	 a	 short	 acyl	 group	 at	 the	 sn-2	 position	 of	
phospholipids	becomes	susceptible	to	hydrolysis	by	Lp-PLA2.	From	this	reaction	
two	 potent	 pro-inflammatory	 and	 pro-atherogenic	 mediators	 are	 generated,	

















Lp-PLA2 gender, age and race 
	
	 Kosaka	 et	 al.	measured	 Lp-PLA2	 activity	 in	 more	 than	 3000	 healthy	
Japanese	 individuals.	Women	expressed	 significantly	 lower	Lp-PLA2	activity	 in	
comparison	to	men	(Kosaka	et	al.,	2001).	This	finding	was	then	confirmed	in	the	
AtheroGene	 study,	 whose	 population	 is	 composed	 by	 patients	 from	 Europe,	
North	America	and	Australia		(Blankenberg	et	al.,	2003).	
	 Similarly	 to	 gender	 differences,	 Lp-PLA2	 activity	 varies	 with	 age.	 It	
increases	with	age	(Kosaka	et	al.,	2001).	However,	only	women	under	50	years	of	
age	 had	 lower	 Lp-PLA2	 activity	 as	 compared	 with	 men.	 Reasons	 for	 this	
difference	may	be	related	to	hormonal	status,	as	hormone	replacement	therapy	
reduces	Lp-PLA2	levels.		
Race-ethnic	 differences	 in	 Lp-PLA2	 distribution	 have	 been	 assessed	 in	





	 Since	 (Hakkinen	 et	 al.,	 1999)	 demonstrated	 the	 presence	 of	 Lp-PLA2	
mRNA	 transcripts	 in	 macrophage-rich	 atherosclerotic	 plaque	 by	 in-situ	
hybridization	and	 immunohistochemical	 analysis,	 suggesting	 that	Lp-PLA2	was	
locally	 synthetized,	 hundreds	 of	 studies	 were	 then	 published	 assessing	 the	
relationship	 between	 the	 Lp-PLA2	 mass	 concentration	 or	 activity	 with	 the	
presence,	prediction	or	prognostication	of	cardiovascular	diseases.			
	 One	 of	 these	 studies	 elucidated	 that	 Lp-PLA2	 increases	 in	 advanced	
coronary	atherosclerotic	plaques	(thin-cap	fibroatheromas	or	ruptured	plaques)	
when	 comparing	 to	 more	 stable	 coronary	 plaques	 (Kolodgie	 et	 al.,	 2006)	
suggesting	an	association	between	Lp-PLA2	and	plaque	 instability.	This	 finding	
was	 then	 confirmed	 for	 atherosclerotic	 plaques	 in	 the	 carotid	 arteries,	
suggesting	an	association	between	Lp-PLA2	and	stroke	(Mannheim	et	al.,	2008).		





2004;	 Persson	 et	 al.,	 2007;	 Daniels	 et	 al.,	 2008;	 Tsimikas	 et	 al.,	 2009),	 small	
density	 LDL	 (Gazi	 et	al.,	 2005),	 obesity	 and	 the	metabolic	 syndrome	 (Persson,	
Hedblad	and	Nelson,	2007).	
	 The	West	of	Scotland	Coronary	Prevention	Study	(WOSCPS)	was	the	first	
study	 to	 propose	 Lp-PLA2	 as	 an	 independent	 risk	 predictor	 for	 cardiovascular	
disease.	The	investigators	found	that	increased	baseline	levels	of	Lp-PLA2	were	
strongly	 associated	 with	 cardiovascular	 events	 even	 after	 adjustment	 for	
traditional	 risk	 factors	and	 inflammatory	markers,	 including	high-sensitivity	C-
reactive	protein	(hs-CRP)	(Packard	et	al.,	2000).	There	was	an	approximate	20%	
increase	 in	 risk	 for	 every	 standard	 deviation	 increase	 in	 Lp-PLA2.	 The	 study	
population	was	composed	of	middle-aged	hypercholesterolemic	men	in	Scotland	
with	high	prevalence	of	other	risk	factors.	




traditional	 risk	 factors	 and	 hs-CRP.	 The	 study	 population	 was	 composed	 of	
middle-aged	American	women	who	were	mostly	professionals	and	had	a	 lower	
event	rate.	
	 The	 AtheroGene	 study	 was	 designed	 to	 compare	 Lp-PLA2	 activity	
between	healthy	subjects	and	patients	with	coronary	artery	disease	(CAD).	CAD	




	 In	 the	Atherosclerosis	 Risk	 in	 Communities	 (ARIC)	 study	 (Ballantyne	 et	
al.,	 2004)	 Lp-PLA2	 mass	 concentration	 and	 hs-CRP	 were	 measured	 in	 1348	
middle-aged	 American	 men	 and	 women	 (including	 a	 substantial	 number	 of	
African	 Americans)	 with	 a	 wide	 range	 of	 LDL-C.	 Lp-PLA2	 and	 hs-CRP	 were	
associated	 to	explore	 the	 increased	risk	 for	 incident	CHD.	Lp-PLA2	and	hs-CRP	
levels	were	higher	in	individuals	who	subsequently	developed	CHD	than	in	those	
who	remained	free	of	CHD.	They	also	divided	the	study	population	in	those	with	
LDL-C	 greater	 or	 lesser	 than	 3.367	mmol/l	 (at	 that	 time,	 American	 guidelines	
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recommended	a	LDL-C	cut-off	of	130	mg/dl	or	3.367	mmol/l	to	initiate	therapy	
with	 statins)	 and	 concluded	 that	 Lp-PLA2	 mass	 and	 the	 risk	 for	 CHD	 was	
substantially	 attenuated	 in	 individuals	 with	 LDL-C	 >3.367	 mmol/l	 after	
adjustment	for	other	risk	factors.	This	means,	that	Lp-PLA2	mass	independently	
predicted	 risk	 of	 incident	 CHD	 only	 among	 individuals	 with	 LDL-C	 <3.367	






Similarly,	 the	Rotterdam	Study	 (Oei	et	al.,	2005)	 found	a	20%	 increased	
risk	 of	 CHD	 for	 each	 standard	 deviation	 increase	 in	 Lp-PLA2	 activity	within	 a	
median	 follow	 up	 of	 6.4	 years	 in	 a	 case-cohort	 study	 including	 2238	men	 and	
women	 ≥55-years	 of	 age	 after	 adjustment	 for	 traditional	 cardiovascular	 risk	
factors.		Of	interest,	no	LDL	cholesterol	levels	were	available,	so	the	investigators	
adjusted	Lp-PLA2	activity	for	non-HDL	cholesterol	levels.	
	 From	 the	Coronary	Artery	Risk	Development	 in	Young	Adults	 (CARDIA)	
study,	266	black	and	white	young	individuals	aged	18-30	years	were	examined	
for	 the	association	of	Lp-PLA2	mass	and	activity	with	 the	presence	of	 calcified	
coronary	 plaque	 ascertained	 by	 cardiac	 computed	 tomography	 (CT).	 Lp-PLA2	
mass	was	 found	 to	 be	 independently	 associated	with	 the	 presence	 of	 calcified	
coronary	 plaque	 and	 the	 amount	 of	 coronary	 calcium	 (Iribarren,	 Gross,	
Darbinian,	 Jr,	 et	 al.,	 2005).	 Lp-PLA2	 activity	 lost	 statistical	 significance	 when	
adjusted	for	other	risk	factors.	
	 The	 Rancho	 Bernardo	 Study	 was	 another	 case-cohort	 study	 that	
evaluated	 Lp-PLA2	 as	 an	 independent	 cardiovascular	 risk	 factor	 in	 1077	
Caucasian	individuals	from	a	southern	California	community	with	a	median	age	
of	72	years	and	without	known	previous	coronary	heart	disease	(CHD).	After	a	
mean	 follow-up	of	 16	 years	 study	participants	were	 classified	 as	 incident	CHD	
cases	 if	 at	 any	 time	 during	 the	 follow-up	 period	 they	 had	 a	 fatal	 or	 nonfatal	
myocardial	 infarction,	 coronary	 revascularization,	 or	 angina	 (grades	 1	 or	 2	 by	





	 More	 recently,	 another	 case-cohort	 study	 tested	 the	 population	 of	 the	
Prospective	 Study	 of	 Pravastatin	 in	 the	 Elderly	 at	 Risk	 (PROSPER)	 for	 the	 Lp-
PLA2	 association	 with	 cardiovascular	 diseases.	 PROSPER	 was	 a	 randomized	
control	trial	of	pravastatin	40	mg	daily	versus	placebo	in	5804	men	and	women	
aged	 70-82	 years	 with	 a	 mean	 follow-up	 of	 3.2	 years,	 and	 with	 the	 primary	
endpoint	 of	 CHD	and	 stroke.	 LDL	was	not	 a	predictor	 of	 CHD	or	 stroke	 in	 this	
trial.	Lp-PLA2	activity	and	mass	concentration	were	measured	in	2804	men	and	
3000	women	and	 they	 found	a	moderately	 association	 for	mass	 concentration,	
but	not	for	activity,	with	CHD	and	stroke	after	adjustment	for	other	risk	factors	
(Caslake	et	al.,	 2010).	Of	note,	 this	 cohort	 included	 selected	elderly	 individuals	
that	previously	have	had	a	stroke	or	a	myocardial	infarction,	or	were	at	high	risk	
for	 such	 an	 event,	which	 gave	 an	 endpoint	 of	 new	or	 recurrent	 cardiovascular	
events.	
	 One	 more	 relevant	 case-cohort	 study	 took	 information	 from	 The	
Cardiovascular	 Health	 Study	 (CHS)	 to	 assess	 Lp-PLA2	 as	 an	 independent	 risk	
factor	 for	 incident	myocardial	 infarction,	stroke	and	CVD	death.	The	aim	of	 the	
initial	study	was	the	 identification	of	risk	 factors	 for	CHD	and	stroke.	From	the	
initial	study	population	composed	of	5888	men	and	women	≥65	years	of	age	at	
baseline,	 Lp-PLA2	 activity	 and	 mass	 concentration	 were	 measured	 in	 3949	
participants.	Lp-PLA2	mass	concentration	was	associated	with	risk	of	myocardial	
infarction	 and	 stroke,	 but	 the	 results	 were	 attenuated	 after	 adjustment	 for	
traditional	 risk	 factors	 and	 statistical	 significance	was	 lost	 for	 stroke	 and	 CVD	
death.	 Lp-PLA2	 activity	 was	 associated	 with	 increased	 risk	 of	 myocardial	















The	 results	 of	 the	 Justification	 for	 the	 Use	 of	 Statins	 in	 Prevention:	 an	
Intervention	 Trial	 Evaluating	 Rosuvastatin	 (JUPITER)	were	 published	 in	 2009.	
This	 randomized,	 double-blind,	 placebo-controlled	 trial	 compared	 rosuvastatin	
20	 mg	 daily	 to	 placebo	 in	 17	 802	 men	 and	 women	 without	 previous	
cardiovascular	 disease	 or	 diabetes	 at	 study	 entry,	 and	 with	 a	 baseline	 LDL-C	
<3.37	mmol/l	and	a	hs-CRP	≥2	mg/l.	The	trial	was	stopped	early	after	a	median	
follow-up	of	1.9	years	because	of	a	44%	reduction	in	the	primary	endpoint	of	all	
vascular	 events,	 a	 54%	reduction	 in	myocardial	 infarction,	 a	 48%	reduction	 in	
stroke,	 a	 46%	 reduction	 in	 the	 need	 for	 arterial	 vascularization,	 and	 a	 20%	
reduction	in	all	cause	mortality.	A	sub-analysis	from	the	JUPITER	trial	evaluated	
the	 relationships	 of	 Lp-PLA2	 activity	 and	mass	 concentration	 with	 the	 risk	 of	
future	 vascular	 events.	 At	 baseline	 Lp-PLA2	mass	 and	 activity	 correlated	with	
each	other	 and	with	LDL-C,	 and	 the	magnitude	of	 those	 correlations	 increased	
after	 statin	 therapy.	 Rosuvastatin	 reduced	 Lp-PLA2	 mass	 concentration	 by	
33.8%,	 Lp-PLA2	 activity	 by	 33.2%,	 and	 LDL-C	 by	 48.7%.	 Levels	 of	 Lp-PLA2	
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activity,	 but	 not	mass,	were	 associated	with	 cardiovascular	 risk.	 However,	 Lp-
PLA2	 no	 longer	 predicted	 risk	 or	modified	 clinical	 outcomes	when	 individuals	
were	 treated	 with	 rosuvastatin	 20	 mg	 daily	 (Ridker	 et	 al.,	 2012).	 This	 trial	
included	 more	 incident	 and	 carefully	 adjudicated	 CVD	 events	 than	 nearly	 all	
prior	epidemiologic	studies	combined.	It	is	also	very	important	in	understanding	
the	 role	 of	 Lp-PLA2	 in	 predicting	 the	 risk	 of	 cardiovascular	 events	 after	
pharmacological	 reduction	 of	 LDL-C,	 non-HDL-C,	 and	 apoB.	 Reductions	 in	 Lp-
PLA2	have	been	attributable	in	part	to	concomitant	reductions	in	LDL-C	or	apoB.	
The	ARIC	study	was	again	mentioned	 in	2015	with	the	expansion	of	 the	
cohort	 to	 15	 792	 participants.	 From	 those	 11	 656	 were	 investigated	 for	 the	
relationship	of	Lp-PLA2	activity	with	apoC3	loss-of-function	(LOF)	variants	and	
the	 risk	 for	 incident	 cardiovascular	 disease	 in	 whites	 and	 African-Americans	
over	a	mean	follow-up	of	11	years.	apoC3	LOF	variants	are	associated	with	lower	
triglycerides	 and	 small	 dense	 LDL-C	 levels	 and	 higher	 HDL-C,	 reduced	
postprandial	 lipemia	 and	 reduced	 CHD	 risk.	 Lp-PLA2	 activity	 was	 associated	




events.	 It	 divided	 the	participants	with	 and	without	 subclinical	 atherosclerosis	
assessed	by	measuring	 the	coronary	artery	calcium	content	by	CT	scan	and	by	
the	 carotid	 intimal	 medial	 thickness.	 5456	 participants	 were	 included	 for	 the	
assessment	 of	 Lp-PLA2	 activity	 and	 mass	 concentration	 as	 a	 predictor	 of	
cardiovascular	 events.	 The	mean	 follow-up	 period	 was	 10.2	 years.	 Higher	 Lp-
PLA2	 activity	 and	 mass	 concentration	 were	 associated	 with	 increased	 risk	 of	
cardiovascular	disease	and	CHD	in	both,	individuals	with	and	without	subclinical	
atherosclerosis	(Garg	et	al.,	2015).		
The	 overwhelming	 majority	 of	 epidemiologic	 studies	 designed	 to	
investigate	 the	 relationship	 between	 Lp-PLA2	 and	 coronary	 events	 in	 patients	
without	prior	history	of	CVD	have	demonstrated	an	association.	This	emerging	
body	 of	 evidence	 suggests	 that	 Lp-PLA2	may	 offer	 added	 value	 to	 established	
risk	factors	in	assessing	cardiovascular	risk.		
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However,	 there	are	 still	 some	questions	 regarding	 the	methodology	and	
interpretation	 of	 these	 positive	 results,	 meaning	 the	 statistically	 significant	
association	 of	 Lp-PLA2	 mass	 or	 activity	 with	 CVD.	 The	 strength	 of	 this	









traditional	 cardiovascular	 risk	 factors.	 Subjects	 in	 the	 highest	 quartile	 had	 an	
almost	doubled	risk	of	a	future	ischemic	stroke	compared	to	those	in	the	lowest	
quartile.	 It	was	 the	 first	 study	 to	 propose	 Lp-PLA2	 activity	 as	 an	 independent	
risk	 factor	 for	 ischemic	stroke.	Of	note,	associations	of	 total	cholesterol,	LDL-C,	
non-HDL	cholesterol	and	HDL	cholesterol	as	risk	factors	for	ischemic	stroke	are	
much	weaker	than	for	myocardial	infarction.	
The	Malmö	Diet	 and	Cancer	 Study	 (MDCS)	was	 designed	 to	 explore	 the	
effects	 of	 diet	 on	 cancer	 risk	 in	 the	 urban	 area	 of	 Malmö,	 Sweden.	 From	 this	
cohort,	5393	individuals	(3162	women	and	2231	men)	were	selected	to	evaluate	
the	associations	of	Lp-PLA2	activity	and	mass	concentration	with	the	incidence	
of	 CHD	 and	 ischemic	 stroke	 within	 a	 mean	 follow-up	 period	 of	 10.6	 years	
(Persson	 et	 al.,	 2008).	 Both,	 Lp-PLA2	 activity	 and	 mass	 concentration	 were	
statistically	 significantly	 associated	 with	 increased	 risk	 for	 incident	 ischemic	
stroke.	In	this	study,	once	again,	LDL-C	did	not	modify	the	association	of	Lp-PLA2	
activity	or	mass	concentration	with	the	risk	 for	 ischemic	stroke.	However,	 they	
did	 not	 find	 any	 statistically	 significant	 independent	 relationship	 between	 Lp-






follow-up	 period.	 They	 concluded	 that	 Lp-PLA2	 activity	 was	 associated	 with	
increased	 risk	 of	 future	 cardiovascular	 events,	 including	 stroke	 or	 transient	
ischemic	attack	and	myocardial	 infarction	 (Tsimikas	et	al.,	2009).	 Interestingly,	
the	 ratio	 of	 oxidized	 phospholipids	 (detected	 by	 a	 monoclonal	 antibodies)	 to	
apoB	levels	predicted	10-year	CVD	event	rates	independently	of	traditional	risk	
factors	in	a	previous	study	from	the	Bruneck’s		cohort	(Kiechl	et	al.,	2007).	
The	 Northern	 Manhattan	 Stroke	 (NOMAS)	 study	 is	 prospective,	
population-based	 cohort	 consisting	 of	 3298	 stroke-free	multiethnic	 individuals	
living	in	New	York,	USA,	and	the	primary	goals	of	the	study	were	to	describe	the	
prevalence	 of	 vascular	 risk	 factors.	 Lp-PLA2	mass	 concentration	was	 available	
for	1946	participants.	Lp-PLA2	mass	concentration	was	associated	with	the	risk	
of	 large	 artery	 atherosclerotic	 stroke	 and	 this	 association	 was	 greater	 among	
non-Hispanic	White	participants,	 but	not	 in	other	ethnic	 groups.	There	was	no	
association	of	Lp-PLA2	with	overall	ischemic	stroke	risk	(Katan	et	al.,	2014).		
As	 for	 the	 prediction	 of	 coronary	 events	 it	 seems,	 that	 the	 results	




Lp-PLA2	 also	 appears	 to	 be	 a	 risk	 factor	 for	 recurrent	 cardiovascular	
events	 among	 patients	 with	 established	 cardiovascular	 disease	 (i.e.	 secondary	
prevention	 populations).	 A	 study	 examining	 individuals	 undergoing	 clinically	
indicated	 angiography	 demonstrated	 that	 higher	 levels	 of	 Lp-PLA2	 were	
associated	 with	 a	 higher	 incidence	 of	 death	 or	 cardiovascular	 event	
independently	of	traditional	CHD	risk	factors	and	C-reactive	protein	over	a	four-
year	follow-up	period	(Brilakis	et	al.,	2005).	Later,	a	prospective	study	included	
1051	 patients	 aged	 30	 to	 70	 years	with	 a	 diagnosis	 of	 coronary	 heart	 disease	












was	 available	 from	 3648	 patients	 (87.7%	 of	 the	 initial	 trial	 population)	 at	 the	
baseline,	 and	 was	 measured	 in	 3265	 participants	 (78.4%	 of	 the	 initial	 trial	
population)	 after	 a	30	days’	 follow-up.	They	 found	an	association	between	Lp-
PLA2	and	the	risk	of	recurrent	cardiovascular	events	by	comparing	patients	with	
Lp-PLA2	activity	 in	 the	highest	quintile	 at	30	days	with	patients	with	Lp-PLA2	
activity	 in	 the	 lowest	 quintile.	 The	 main	 result,	 however,	 was	 an	 expecting	
decline	 in	 overall	mean	 Lp-PLA2	 activity	 (by	 12.7%)	 after	 initiating	 treatment	
with	 a	 statin	 (atorvastatin	 80	mg	 daily	 or	 pravastatin	 40	mg	 daily).	 However,	





of	 LDL-C	 (Donoghue	 et	 al.,	 2006).	 	 The	 initial	 trial	 (Cannon	 et	 al.,	 2004),	
composed	 of	 4162	patients,	 compared	 the	 effects	 of	 intensive	 (atorvastatin	 80	
mg	 daily)	 versus	 moderate	 (pravastatin	 40	 mg	 daily)	 statin	 therapy	 for	 the	
prevention	of	major	adverse	cardiac	events	after	acute	coronary	syndrome.	
The	 2	 other	 studies	 (FRISC	 II	 and	 GUSTO	 IV)	 were	 analyzed	 together.	
FRISC	 II	 was	 a	 Scandinavian	 prospective,	 randomized,	 multicenter	 study	
designed	 to	 evaluate	 early	 non-invasive	 or	 invasive	 strategies	 and	 long-term	
treatment	with	dalteparin	or	placebo	in	patients	with	acute	coronary	syndrome.	
Out	of	2457	patients,	1362	were	analyzed	for	Lp-PLA2	mass	concentration.	The	
GUSTO	 IV	 was	 a	 prospective,	 randomized,	 multicenter	 study	 involving	 24	
countries	 and	 7800	 patients	 with	 non-ST-elevation	 acute	 coronary	 syndrome	







Factors	 and	 Recurrent	 Coronary	 Events	 (THROMBO)	 postinfarction	 study,	




The	 Veterans	 Affairs	 HDL	 Intervention	 Trial	 (VA-HIT)	 was	 a	 placebo-
controlled,	 5	 year	 intervention	 trial	 with	 gemfibrozil	 1.2	 grams	 daily	 to	
determine	whether	raising	a	low	HDL-C	(mean	at	baseline	0.83	mmol/l)	in	men	
with	known,	stable	CHD	and	a	low	LDL-C	(mean	at	baseline	2.87mmol/l)	would	
reduce	 the	 major	 cardiovascular	 events	 of	 nonfatal	 myocardial	 infarction	 and	
CHD	death.	From	the	included	2175	men	in	this	trial,	1451	(725	taking	placebo,	
726	taking	gemfibrozil)	were	selected	for	measurements	of	Lp-PLA2	activity.	In	
multivariate	 analyses,	 adjusted	 for	 major	 cardiovascular	 risk	 factors,	 elevated	
Lp-PLA2	activity	at	baseline,	as	well	as	after	6	to	7	months	in	the	study,	predicted	
a	 significant	 increase	 in	 the	 combined	 endpoint	 of	myocardial	 infarction,	 CHD	
death	 and	 stroke	 over	 the	 5-year	 period	 of	 trial	 (Robins	 et	 al.,	 2008).	 These	
results	supported	the	hypothesis	that	Lp-PLA2	can	be	used	as	a	risk	stratification	
tool	in	patients	with	stable	coronary	diseases.	
From	The	Heart	 Protection	 Study	Collaborative	Group	 (HPSCG)	 another	
case-cohort	 analysis	measured	 Lp-PLA2	 activity	 and	mass	 concentration	 in	 19	
037	individuals	in	a	randomized	trial	of	40	mg	simvastatin	daily	versus	placebo	
and	within	a	mean	follow-up	period	of	5	years.	They	included	participants	with	a	
previous	 diagnosis	 of	 cerebrovascular	 disease,	 CHD,	 other	 occlusive	 disease	 of	
non-coronary	arteries,	diabetes	mellitus	(type	1	or	2),	and	men	aged	65	or	older	
being	 treated	 for	 hypertension.	 Lp-PLA2	 activity	 and	mass	 concentration	were	







At	 this	 stage	 we	 should	 analyze	 the	 results	 of	 the	 well	 conducted	 and	
robust	 JUPITER	(for	primary	cardiovascular	events)	and	HPSCG	(for	secondary	
cardiovascular	events)	 trials.	Together	 they	evaluate	almost	37	000	(17	802	 in	
the	 JUPITER	 and	 19	 037	 in	 the	 HPSCG	 trials)	 individuals	 taking	 statins.	 Once	
patients	were	 treated	with	 effective	 statin	 doses,	 the	 relationship	between	Lp-




value	 in	 risk	 stratification	 and	 whether	 it	 alters	 treatment	 decisions.	 Of	
importance	 is	 that	 the	 reduction	 in	 CVD	 in	 these	 trials	 was	 not	 modified	 by	
baseline	Lp-PLA2	values	and	any	apparent	relationship	of	Lp-PLA2	to	CVD	risk	
was	ameliorated	by	 the	 statins	 (Stein,	2012).	This	makes	 the	measurements	of	
Lp-PLA2	 activity	 or	 mass	 concentration	 of	 very	 limited	 use	 in	 patients	 being	
treated	 with	 statins,	 meaning	 all	 patients	 after	 a	 cardiovascular	 event	 (as	
secondary	prevention)	and	 in	a	considerable	proportion	of	patients	 in	primary	
prevention.	
The	 Ludwigshafen	 Risk	 and	 Cardiovascular	Health	 study	 included	 2298	
patients	 with	 and	 661	 patients	 without	 angiographically	 confirmed	 CAD	 in	 a	
follow-up	 period	 of	 8	 years.	 Lp-PLA2	 mass	 concentration	 was,	 independently	




or	 unstable	 angina	 to	 receive	 placebo	 or	 pravastatin	 3	 to	 36	months	 after	 the	
initial	 event.	 From	 the	 study	 population,	 7863	 patients	 had	 baseline	
measurement	 of	 Lp-PLA2	 activity,	 which	 was	 positively	 associated	 with	 CHD	
events	in	a	follow-up	period	of	6	years,	but	not	after	adjustment	for	23	baseline	









moment	of	diagnosis,	 they	were	 followed-up	 to	determine	predictors	of	 stroke	
recurrence	and	prognosis.	Lp-PLA2	activity	was	available	for	467	participants	at	
baseline	 and	 the	 median	 follow-up	 was	 4.0	 years.	 After	 adjustment	 for	
traditional	 cardiovascular	 risk	 factors,	 Lp-PLA2	 activity	 continued	 to	 have	 an	
increased	 risk	 of	 recurrent	 stroke	 (Elkind	 et	 al.,	 2009).	 Patients	 in	 the	 top	
quartile	 had	 approximately	 2.5	 times	 increased	 risk	 of	 stroke	 recurrence	 as	
those	in	the	first	quartile,	event	after	adjusting	for	other	risk	factors.	
	 A	 subset	 of	 3201	 participants	 enrolled	 in	 the	 Clopidogrel	 in	 High-Risk	
Patients	with	Acute	Non-disabling	Cerebrovascular	Events	(CHANCE)	trial	were	




225	 nmol/min/mL	 had	 a	 30%	 increased	 short-term	 risk	 of	 recurrent	 vascular	
events	(Lin	et	al.,	2015).	
	 A	more	recent	prospective	study	measured	Lp-PLA2	mass	concentration	
in	 179	 cases	 of	 acute	 cerebral	 infarction	 confirmed	 by	 magnetic	 resonance	
imaging.	 Lp-PLA2	 mass	 concentration	 was	 significantly	 elevated	 in	 these	
individuals	at	presentation	comparing	to	149	individuals	without	acute	cerebral	







	 Because	of	 the	 inconclusive	 results	of	previous	epidemiologic	 individual	
studies	 several	 recent	 meta-analyses	 tried	 to	 find	 consensus	 in	 assessing	 Lp-
PLA2	activity	or	mass	concentration	as	a	predictor	of	cardiovascular	diseases.		
	 The	 LpPLA2	 Studies	 Collaboration	 group	 performed	 the	 first	 relevant	
meta-analysis.	They	gathered	information	from	32	prospective	studies	including	
a	 total	of	79	036	 individuals	and	concluded	 that	elevated	Lp-PLA2	activity	and	
mass	 concentrations	 were	 associated	 with	 increased	 risks	 for	 CHD	 events,	
ischemic	stroke	and	vascular	and	non-vascular	mortality	in	a	continuous	manner	
within	a	follow-up	period	of	6	years	(Thompson	et	al.,	2010).	However,	they	also	
conclude	 that	 since	 Lp-PLA2	 is	 physically	 linked,	 through	 apoB,	with	 LDL,	 the	
validity	of	statistical	attempts	to	distinguish	the	effects	of	Lp-PLA2	from	those	of	
proatherogenic	 lipids	 remains	 uncertain.	However,	 this	meta-analysis	 included	
both	 participants	 with	 and	 without	 a	 history	 of	 vascular	 disease.	 A	 subgroup	
analysis	 among	 individuals	 without	 prior	 vascular	 disease	 showed	 no	 such	
associations.	 Furthermore,	 not	 all	 the	 assays	 used	 for	 the	measurement	 of	 Lp-
PLA2	mass	perform	similarly.	
	 In	 the	 end	 of	 2016,	 a	 second	 meta-analysis	 was	 published.	 It	 included	
fifteen	 prospective	 observational	 studies	 comprising	 a	 total	 of	 30	 857	
participants	 with	 CHD.	 Lp-PLA2	was	 independently	 associated	with	 long-term	
cardiovascular	 events	 in	 patients	 with	 CHD,	 but	 not	 with	 long-term	 all-cause	
mortality	 in	 patients	 with	 CHD.	 The	 investigators	 did	 not	 find	 the	 prognostic	
value	 of	 Lp-PLA2	 for	 predicting	 cardiovascular	 events	 in	 patients	 with	 acute	
coronary	 syndrome.	 They	 further	 suggested	 that	 differences	 in	 methodology	
(manual	 versus	 automated	 ELISA	 assays)	 could	 in	 part	 explain	 the	 results	 (Li,	
Zhao,	 et	 al.,	 2017).	 This	 meta-analysis	 was	 focused	 on	 the	 prediction	 of	
secondary	cardiovascular	events.	
	 Later,	 in	2017	the	same	group	published	a	meta-analysis	 for	the	general	
population	 (prediction	 of	 primary	 cardiovascular	 and	 ischemic	 stroke	 events).	
12	 studies	 comprising	 44	 187	 participants	 were	 included.	 Individuals	 had	 an	
average	 age	 of	 63	 years,	 48.2%	 of	 them	were	males,	 and	 the	mean	 follow-up	







attack	 or	 were	 after	 a	 first	 ischemic	 stroke	 and	 16	 239	were	 residents	 in	 the	
general	 population.	 The	 follow-up	 period	 varied	 from	 30	 days	 to	 11	 years.	
Patients	 with	 transient	 ischemic	 attack	 and/or	 primary	 ischemic	 stroke	 who	
exhibited	 elevated	 blood	 levels	 of	 Lp-PLA2	 activity	 were	 at	 higher	 risk	 of	
developing	 recurrent	 vascular	 events	 (Tian	 et	 al.,	 2017).	 For	 the	 general	
population	 Lp-PLA2	mass	 concentration,	 but	 not	 activity,	 was	 associated	 with	
the	risk	of	stroke.								
Worthful	mentioning	 is	 yet	 another	Asian	meta-analysis	 that	 included	8	
studies	 comprising	 46	 034	 participants.	 Neither	 Lp-PLA2	 activity	 or	 mass	
concentration	were	 associated	with	 ischemic	 stroke	 and	Lp-PLA2	 could	not	be	
considered	a	risk	factor	for	ischemic	stroke	(Xia,	Hu	and	Song,	2017)	









16%.	 The	 stroke	 risk	 was	 not	 increased	 in	 patients	 with	 baseline	 CHD.	 The	







Due	 to	 these	 inconclusive	 results	 mentioned	 above	 we	 need	 a	 better	
understanding	of	the	Lp-PLA2	function.	Lp-PLA2	effects	may	substantially	differ	
whether	it	is	bound	to	LDL	or	to	HDL	particles.	Lp-PLA2	activity	and	HDL	levels	
are	often	 inversely	associated,	but	this	 is	 likely	explained	by	the	fact	 that	small	
dense	LDL	(with	high	Lp-PLA2	activity)	 is	more	abundant	 in	subjects	with	 low	




The	 first	 such	 study	 evaluated	 a	 Japanese	 population	 and	 identified	 an	
association	between	a	missense	mutation	in	exon	9	of	the	Lp-PLA2	gene	(G994	to	
T)	with	myocardial	 infarction	 in	men,	but	not	 in	women	(Yamada	et	al.,	1998).	
This	nucleotide	change	results	 in	 the	substitution	of	valine	by	phenylalanine	at	
the	amino	acid	residue	279,	which	induces	loss	of	Lp-PLA2	catalytic	activity.	The	
authors	 proposed	 that	 the	 loss	 of	 function	 of	 Lp-PLA2	 is	 associated	 with	
increased	 risk	 for	myocardial	 infarction.	 Later	 on,	 it	was	 discovered	 that	 such	
mutation	 is	 commonly	 found	 in	 East	 Asians	 and	 affects	 about	 25%	 of	 the	
Japanese	 population.	 The	 prevalence	 of	 such	 mutation	 declines	 when	 moving	
towards	 the	 West,	 with	 intermediate	 frequencies	 in	 China	 and	 Korea,	
substantially	 lower	 frequencies	 in	 the	 Middle	 East,	 and	 an	 almost	 completely	
absence	 in	 the	 European	 population.	 Thus,	 the	 results	 from	 the	 association	




used	 data	 from	 6668	 Caucasian	 subjects	 included	 in	 the	 Framingham	 Heart	
Study	and	identified	polymorphisms	at	several	loci	that	may	contribute	to	inter-
individual	 variations	 in	Lp-PLA2	activity	 and	mass	 concentration.	 For	Lp-PLA2	
activity,	polymorphisms	at	4	independent	loci	reached	genome-wide	significance	
including	 APOE/APOC1	 region	 on	 chromosome	 12,	 CELSR2/PSRC1	 on	
chromosome	 1,	 SCARB1	 on	 chromosome	 12	 and	 ZNF259/BUD13	 in	 the	
APOA5/APOA1	 gene	 region	 on	 chromosome	 11.	 For	 Lp-PLA2	 mass,	 12	 single	
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nucleotide	 polymorphisms	 (SNPs)	 achieved	 genome-wide	 significance,	 all	
clustering	 in	 a	 region	 on	 chromosome	 6p12.3	 near	 the	 PLA2G7	 gene,	 which	
encodes	for	Lp-PLA2	(Suchindran	et	al.,	2010).		
Grallert	 et	 al.	 who	 made	 a	 meta-analysis	 with	 4	 additional	 cohorts,	
achieving	 a	 population	 of	 13	 664	 subjects,	 followed	 these	 investigations.	 This	





For	 Caucasians,	 the	 missense	 polymorphisms	 I198T	 and	 A379V	 were	
identified.	 In	 the	 later,	 alanine	 is	 substituted	 by	 valine	 and	 this	mutation	was	
shown	 to	 be	 involved	 in	 changes	 in	 Lp-PLA2	 activity.	 However,	 some	 studies	
related	 this	variant	with	an	 increase	 (Ninio	et	al.,	 2004;	Hoffmann	et	al.,	 2009)	
and	some	with	a	decreased		(Liu	et	al.,	2006)	in	Lp-PLA2	activity	not	allowing	for	
generalizations.	 Further	 studies	 evaluated	 this	 mutation	 for	 associations	 with	
cardiovascular	 diseases	 and,	 again,	 the	 results	 were	 very	 contradictory,	 and	
mainly	influenced	by	the	ethnicity	of	the	study	population	(A379V	mutation	was	
associated	with	 increased	 severity	 of	 coronary	 atherosclerosis	 in	 a	 Taiwanese	
population	 and	with	decreased	 atherosclerotic	 risk	 in	Caucasians).	 In	 addition,	




examining	 V279F	 variants	 were	 based	 on	 Asian	 populations	 and	 there	 was	 a	





atherosclerosis	 were	 found.	 Concerning	 R92H	 polymorphism	 6	 studies	 were	
included	for	analysis.	Caucasians	comprised	57%	of	the	population.	There	was	a	
significant	 positive	 association	 of	 R92H	 polymorphism	 with	 clinical	
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atherosclerosis.	 This	 association	 has	 been	 translated	 into	 increased	 levels	 of	
plasma	Lp-PLA2	(gain	of	function).	Lastly,	4	studies	were	including	for	the	I198T	
polymorphism.	 Caucasians	 comprised	 50,7%	 of	 the	 population,	 the	 remaining	
were	Asians.	No	significant	association	with	atherosclerosis	was	found	(Santoso	
et	al.,	2017).	
	 In	 conclusion,	 despite	 genome	 studies	 extensively	 evaluated	 several	






Due	 to	 the	 immense	 body	 of	 evidence	 shown	 in	 this	 paper,	
pharmacological	 inhibition	of	Lp-PLA2	 is	a	natural	step	 to	keep	on	researching	
Lp-PLA2	and	its	role	in	CVD.		
In	 2003	 a	 potent	 and	 reversible	 inhibitor	 of	 Lp-PLA2	 (darapladib)	 was	
identified	 and	 tested	 in	 human	 whole	 plasma,	 in	 Watanabe	 hereditable	
hyperlipidemic	rabbit	plasma	and	then	in	rats	as	an	oral	formulation	(Blackie	et	
al.,	 2003).	 Darapladib	 was	 then	 tested	 in	 the	 diabetes	 mellitus	 and	
hypercholesterolemia	 porcine	 model	 of	 accelerated	 atherosclerosis.	 After	 a	
period	of	induction	(4	weeks)	Lp-PLA2	activity	was	increased	by	approximately	
230%	 compared	 to	 the	 levels	 at	 baseline.	 Treatment	 with	 darapladib	 was	
initiated	at	4	weeks	and	resulted	 in	a	significant	reduction	of	Lp-PLA2	activity,	
lead	 to	 a	 reduction	 in	 the	 development	 of	 coronary	 atherosclerosis	 (treated	
lesions	 were	 less	 severe,	 contained	 fewer	 macrophages,	 and	 showed	 smaller	
necrotic	 cores),	 and	 inhibited	 the	 subsequent	 progression	 to	 advanced	 lesions	




coronary	 disease	 angiographically	 was	 performed	 (Serruys	 et	 al.,	 2008).	
Darapladib	 prevented	 the	 expansion	 of	 the	 necrotic	 core	 when	 compared	 to	
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patients	 receiving	 placebo,	 where,	 despite	 a	 high	 level	 of	 standard-of-care	
treatment,	the	necrotic	core	continued	to	expand.		
After	 these	 promising	 results	 a	 double-blind	 trial,	 the	 STABILITY	 trial	




addition,	 the	presence	of	at	 least	one	more	risk	 factor	was	required	 (age	of	60	
years	or	older,	diabetes	mellitus	requiring	pharmacotherapy,	HDL-C	of	less	than	
1,03	 mmol/L,	 smoker,	 moderate	 renal	 dysfunction	 or	 polyvascular	 arterial	




	 Shorter	 after,	 another	 double-blind,	 placebo-controlled	 trial,	 the	 SOLID-
TIMI	 52	 (The	 Stabilization	 Of	 pLaques	 usIng	 Darapladib-Thrombolysis	 In	
Myocardial	 Infarction	 52)	 involving	 13,026	 patients	 revealed	 no	 reduction	 in	
major	coronary	events	when	darapladib	was	added	to	standard	of	care	after	an	
acute	coronary	syndrome	(Donoghue	et	al.,	2015).	
	 These	disappointing	results	might	be,	 in	part,	related	with	a	 lack	of	fully	
understanding	 of	 the	 Lp-PLA2	 physiology	 and	 function.	 Performing	 multiple	











on	 the	 current	 proposed	 concepts	 for	 the	 pathogenesis	 and	 development	 of	




being	 ubiquitous,	 it	 is	 not	 a	 surprise,	 that	 atherosclerosis	 is	 the	main	 cause	 of	
death	and	premature	disability	worldwide.	Thirdly,	the	thought	of	this	process	to	
be	caused	by	mere	fatty	deposits	causing	obstructions	in	the	arterial	bed	is	long	
ago	 completely	 refuted.	 Nowadays,	 atherosclerosis	 is	 seen	 as	 a	 complex	 and	
chronic	 inflammatory	 process	 involving	 highly	 specific	 cellular	 and	 molecular	
interactions	 that	 may	 culminate	 with	 the	 rupture	 of	 a	 plaque	 and	 the	
development	of	an	acute	clinical	event,	such	as	myocardial	infarction,	stroke,	or	
sudden	cardiac	death.	This	model	is	also	called	the	response-to-injury	hypothesis	
and	 LpPLA2	 definitely	 plays	 a	 considerable	 role	 in	 this	 process.	 Fourthly,	
atherogenesis	occurs	over	a	period	of	decades	and	the	growth	of	plaques	is	not	







The	 “fatty	 streak”	 (sometimes	 also	 called	 xanthoma)	 represents	 the	
earliest	 lesion	 of	 atherosclerosis.	 This	 lesion	 appears	 at	 very	 young	 age	 and	 is	
present	 in	 virtually	 all	 children	 older	 than	 10	 years,	 regardless	 of	 genetic,	
clinical,	 or	 dietary	 risk	 factors.	 Although	 “fatty	 streaks”	 can	 evolve	 into	
atherosclerotic	 plaques,	 not	 all	 progress.	 	 They	 seem	 to	 arise	 from	 focal	
endothelial	dysfunction	or	injury	within	a	morphological	intact	endothelium	and	
are	 characterized	by	 local	 increases	 in	 the	 amount	of	 lipoproteins	 that	 bind	 to	
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components	 of	 the	 extracellular	 matrix,	 such	 as	 glycosaminoglycans,	
proteoglycans	 (previously	 known	 as	mucopolysaccharides),	 and	 glycoproteins.	
This	 can	 impair	 lipoprotein	 function	 and	 slow	 down	 the	 ability	 to	 clear	 lipid	
particles	 from	 the	 arterial	 wall.	 By	 staying	 longer	 time,	 lipids	 are	 prone	 to	








lipoproteins,	 but	 also	 by	 cytokines,	 such	 as	 interleukin-1	 (IL-1)	 and	 tumor	
necrosis	 factor	α	(TNF-α).	Chemoattractant	cytokines	 then	direct	 the	migration	
of	leukocytes	into	the	arterial	wall.	
Normal	 laminar	blood	 flow	 in	a	pulsatile,	ordered	manner	 increases	 the	
production	of	nitric	oxide	(NO)	from	L-arginine	by	endothelial	cells	through	the	
action	of	NO	synthase.	NO	is	known	by	its	vasodilator	properties,	by	increasing	
cyclic	 guanosine	monophosphate	 (cGMP)	 levels,	 but	 it	 also	 acts	 as	 a	 local	 anti-
inflammatory	 autacoid	 (i.e.	 a	 local	 hormone),	 limiting	 the	 expression	 of	 local	
adhesion	 molecules	 and	 thus,	 inhibiting	 leukocyte	 adhesion	 and	 activation,	
platelet	aggregation	and	smooth	muscle	proliferation.	
On	the	other	hand,	disturbed	blood	flow	decreases	the	production	of	NO	
and	 is	 encountered	 in	 branch	 points,	 making	 these	 predisposed	 sites	 for	 the	




particles,	 major	 components	 of	 the	 atherosclerotic	 plaque.	 Myeloperoxidases	
released	 from	 these	 inflammatory	 cells	 yield	 chlorinated	 species	 such	 as	
chlorotyrosyl	moieties,	which	can	also	chlorinate	HDL	particles.	This	impairs	the	
reverse	 cholesterol	 transport	 resulting	 in	 the	 inability	 to	 clear	 lipid	 particles	
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cytokines,	 such	 as	 CD40L,	 thrombospondin,	 and	 PAF	 (Pant	 et	 al.,	 2014).		
Furthermore,	 they	 promote	 fibrosis	 of	 the	 atherosclerotic	 plaque	 by	 releasing	
platelet-derived	growth	 factor	 (PDGF)	 and	 transforming	growth	 factor	β	 (TGF-
β),	and	increase	smooth	muscle	migration	and	proliferation	(acting	on	protease-
activated	 receptors).	 They	 are	 recruited	 in	 large	 amounts	 once	 microscopic	
breaches	 in	 endothelial	 integrity	 occur.	 These	 breaches	 expose	 highly	
thrombogenic	extracellular	matrix	forming	platelet-rich	microthrombi.	Oxidized	
LDL	also	 stimulates	platelet	 aggregation	 in	 response	 to	adenosine	diphosphate	
(ADP)	and	thrombin.	
The	 inflammatory	 process	 is	 further	 amplified	 by	 the	 release	 of	 large	
amounts	 of	 reactive	 oxygen	 species	 (ROS),	 such	 as	 superoxide	 and	 hydrogen	
peroxide,	 in	 all	 stages	 of	 atherosclerosis.	 ROS	 have	 multiple	 important	
consequences.	 They	 denaturate	 NO,	 activate	 platelets,	 induce	 smooth	 muscle	
proliferation,	 oxidize	 proatherogenic	 lipids	 including	 LDL,	 and	 act	 as	
chemoattractants.	 Oxidized	 LDL	 then	 induces	 the	 release	 of	 more	




migration	 phase	 follows.	 This	 process	 is	 also	 known	 as	 diapedesis.	 It	 requires	
rapid	 disassembly	 of	 the	 leukocyte	 cytoskeleton	 on	 the	 apical	 surface	 of	 the	
endothelium	and	its	reassembly	on	the	abluminal	side	(Muller,	2003).	Junctional	
adhesion	 molecules,	 platelet-endothelial-cell	 adhesion	 molecule-1	 (PECAM-1,	
CD31),	 CD99,	 vascular-endothelial	 cadherin,	 cadherin	 5	 and	 CD144	 are	 the	
responsible	molecules	aiding	this	process.	Each	one	of	them	has	a	crucial	role	in	







endocytosis	 through	 scavenger	 receptors	 and	 it	 is	 not	 regulated	 by	 LDL	
receptors	 as	 explained	 by	 the	 fact	 that	 individuals	 with	 homozygous	 familial	
hypercholesterolemia	have	also	foam	cells	in	their	arterial	walls.		
	 Foam	cells	and	reverse	cholesterol	transport	provided	by	intact	HDL	may	
delay	 the	 formation	 of	 an	 atherosclerotic	 plaque.	 Once	 the	 amount	 of	 lipid	
entering	 the	 arterial	 wall	 exceeds	 that	 removed,	 foam	 cells	 accumulate	 and	
expand	the	intimal	lesion.	Some	of	them	may	then	die	by	apoptosis	resulting	in	










in	 the	 infrarenal	 aorta,	 coronary	 arteries,	 popliteal	 arteries,	 internal	 carotid	
arteries,	and	in	the	circle	of	Willis.		




structure	 covered	 by	 a	 fibrous	 cap	 under	 which	 there	 is	 smooth	 muscle	 cell	
migration	 and	 proliferation	 induced	 by	 cytokine	 production	 (by	macrophages,	
foam	 cells,	 lymphocytes,	 and	 by	 smooth	 muscle	 cells	 themselves).	 Of	 crucial	
importance	are	IL-1	and	TNF-α,	which	induce	the	local	production	of	growth	and	
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Not	 all	 recruited	 macrophages	 however	 exert	 in	 a	 proinflammatory	
fashion.	As	mentioned	earlier,	the	main	goal	of	inflammatory	cells	recruitment	is	
to	resolve	the	lipid	accumulation	at	the	arterial	wall.	Because	of	this	notion,	some	
macrophages	 will	 express	 an	 M2-like	 phenotype,	 favoring	 the	 resolution	 of	
inflammation	by	secreting	factors	such	as	TGF-β.	While	others,	driven	by	binding	
of	 modified	 (e.g.	 oxidized)	 LDL	 to	 pattern-recognition	 receptors	 (e.g.	 Toll-like	
receptors)	 will	 express	 an	 M1-like	 phenotype,	 secreting	 proinflammatory	
cytokines	(e.g.	TNF-α	and	IL-1β),	reactive	oxygen	species,	myeloperoxidases,	etc.	
Lp-PLA2	 expression	 is	 increased	 by	 M1	 (but	 not	 by	 M2)	 macrophages,	 which	
emphasizes	 the	 important	 role	 of	 inflammation	 in	 the	 regulation	 of	 Lp-PLA2	
secretion.	
Lymphocytes	 appear	 in	 the	 atherosclerotic	 lesion	with	 the	 formation	 of	
foam	cells.	T	helper	1	lymphocytes	secrete	proinflammatory	cytokines	(e.g.	TNF-
α	and	interferon-γ,	INF-	γ),	while	regulatory	T	cells,	and	possible	B	cells,	have	an	
anti-inflammatory	 function.	 Increased	 levels	 of	 Lp-PLA2	 and	




to	 a	 fibroatheroma.	 The	 term	 necrotic	 core	may	 be	misleading	 (at	 least	 in	 the	
initial	stages)	because	 it	 is	characterized	by	the	presence	of	acellular,	 lipid-rich	
material	 in	 the	 intima	 and	 not	 necessarily	 by	 the	 morphological	 presence	 of	
death	cells	from	previously	living	tissue	or	cells.	These	become	only	part	of	the	
necrotic	 core	when	 the	 removal	 of	 apoptotic	 remnants	 by	M2	macrophages	 is	
impaired.	 If	 these	 M2	 macrophages	 are	 not	 quickly	 able	 to	 remove	 apoptotic	
remnants,	 they	 accumulate	 in	 the	 M2	 macrophage	 endoplasmatic	 reticulum	
promoting	 their	 own	 apoptosis.	 This	 leads	 to	 the	 release	 of	 lipids,	 pro-
inflammatory	 mediators	 and	 metalloproteinases.	 The	 apoptotic	 remnants	
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undergo	 secondary	 necrosis.	 	 As	 the	 plaque	 grows,	 apoptotic	 foam	 cells	 and	
smooth	muscle	cells	are	mainly	seen	at	its	margins,	whereas	at	the	core	there	is	a	
necrotic	 mass	 of	 debris,	 containing	 large	 amounts	 of	 oxidized	 phospholipids	
(because	 of	 low	 clearance	 and	 auto-oxidation).	 These	 contribute	 to	 the	
expansion	 of	 the	 necrotic	 core,	 neovessel	 injury,	 intraplaque	hemorrhages	 and	
plaque	instability.		
Angiogenesis	
	 As	 atherosclerotic	 lesions	 advance,	 abundant	 plexuses	 of	 microvessels	
develop	in	connection	with	the	artery’s	adventitial	vasa	vasorum.	They	provide	
an	 alternative	 entry	 pathway	 for	 the	 recruitment	 of	 more	 inflammatory	 cells,	
increase	 the	 flow	 of	 nutrients	 and	 oxygen,	 and	 may	 thereby	 promote	 plaque	
progression	and	remodeling.	Like	neovessels	in	the	diabetic	retina,	neovessels	of	
the	atherosclerotic	plaque	are	very	fragile,	 lack	supporting	cells	and	easily	 leak	
resulting	 in	 intraplaque	 focal	 hemorrhages,	 which	 can	 provoke	 thrombosis	 in	
situ,	 yielding	 local	 thrombin	 generation,	 which	 in	 turn	 can	 activate	 smooth	
muscle	 and	 endothelial	 cells	 through	 ligation	 of	 protease-activated	 receptors.	
Once	 again,	 there	 is	 a	 perpetuation	 of	 the	 inflammatory	 vicious	 cycle	 because	
specialized	macrophages	 (of	 the	hemoglobin-induced	phenotype)	 are	 recruited	
into	 the	 plaque	 to	 remove	 the	 haptoglobin-bound	 hemoglobin	 protecting	 the	
plaque	 against	 the	 cytotoxic	 effects	 of	 free	 hemoglobin.	 Individuals	 with	




	 The	 inflammatory	 process	 and	 relative	 hypoxic	 conditions	 within	 the	
atherosclerotic	 plaque	 induce	 the	 expression	 of	 angiogenic	 factors,	 such	 as	
vascular-endothelial	 growth	 factor	 (VEGF),	 hypoxia-inducible	 factor,	
angiopoietin,	PDGF,	etc.	 (Camaré	et	al.,	2017).	Lipids	(e.g.	cholesterol),	oxidized	
lipids	(e.g.	phospholipids),	and	oxidized	lipoproteins	(e.g.	oxidized	LDL)	promote	




	 The	migration	 and	 proliferation	 of	 smooth	muscle	 cells	 from	 the	media	
into	 the	 intima	 of	 the	 arterial	 wall,	 where	 the	 necrotic	 core	 is	 located,	 is	




muscle	 myosin	 heavy	 chain).	 Initially,	 the	 newly	 formed	 connective	 tissue	 is	
mainly	loose	and	fibrocellular.	Then,	it	is	replaced	by	collagen-rich	fibrous	tissue,	
which,	 as	 the	 plaque	 advances,	 becomes	 its	 main	 component.	 This	 relative	
paucity	 of	 smooth	 muscle	 cells	 in	 advanced	 atheromata	 may	 result	 from	 the	
predominance	 of	 cytostatic	 mediators	 such	 as	 TGF-β	 and	 INF-γ,	 and	 from	 the	
apoptosis	of	smooth	muscle	cells.		
	 Apoptotic	cells,	extracellular	matrix,	and	necrotic	core	material	may	act	as	
nidus	 for	 microscopic	 calcium	 granules,	 which	 subsequently	 expand	 to	 form	
larger	lumps	and	plates	of	calcium	deposits	(Bentzon	et	al.,	2014).	Calcification	of	
the	 atherosclerotic	 plaque	 shares	most	 of	 the	 features	 of	 bone	mineralization;	
hence	 many	 proteins	 found	 in	 bone	 are	 also	 located	 in	 the	 plaque	 (e.g.	
osteocalcin,	osteopontin,	and	bone	morphogenic	proteins).	
	 The	 evolution	 of	 the	 atherosclerotic	 plaque	 results	 from	 the	 balance	
between	1)	 leukocytes	 and	 lipoproteins	 entering	 and	 exiting	 the	 lesion,	 2)	 cell	
proliferation	 and	 cell	 death,	 and	 3)	 extracellular	 matrix	 production	 and	
remodeling,	 calcification,	and	neovascularization.	Multiple	and	often	competing	








to	 keep	 in	 mind,	 that	 until	 the	 burden	 of	 the	 atherosclerotic	 plaque	 does	 not	
exceed	 approximately	 40%	 of	 the	 area	 encompassed	 by	 the	 internal	 elastic	
lamina,	the	plaque	does	not	reduce	the	arterial	lumen.	In	other	words,	in	most	of	
its	 life	history	 the	growth	of	 the	atheroma	 is	abluminal	 (outwards),	preserving	
the	 caliber	 of	 the	 lumen.	 This	 phenomenon	 accounts	 in	 part	 for	 the	
underestimation	 power	 of	 arteriografies	 in	 the	 diagnosis	 of	 atherosclerotic	
plaques.	
	 If	the	growth	of	the	plaque	is	steady	and	chronic,	the	lumen	of	the	vessel	
eventually	 becomes	 stenotic,	 leading	 to	 the	 development	 of	 the	 clinical	





no	 time	 for	 the	 formation	 of	 collateral	 vessels,	 and	 the	 fibrous	 cap	 of	 the	
atherosclerotic	plaque	ruptures,	exposing	the	highly	thrombogenic	collagen	and	
	 39	
tissue	 factor,	 and	 leading	 to	 thrombosis	 of	 the	 vessel	 with	 devastating	
consequences	(such	as	acute	coronary	syndromes	and	sudden	cardiac	death).		
	 A	 ruptured	plaque	 is	 defined	 as	 a	 “plaque	 with	 deep	 injury	 with	 a	 real	
defect	 or	 gap	 in	 the	 fibrous	 cap	 that	 had	 separated	 its	 lipid-rich	 atheromatous	
core	 from	 the	 flowing	 blood,	 thereby	 exposing	 the	 thrombogenic	 core	 of	 the	
plaque”	(Schaar	et	al.,	2004).	No	other	confusing	terminology,	such	as	disruption	
or	 fissuring	 should	 be	 used.	 When	 thrombosis	 is	 present,	 but	 there	 are	 no	
microscopic	signs	of	plaque	rupture,	the	term	plaque	erosion	is	used	(Quillard	et	
al.,	 2017).	 This	 erosion	 is	 characterized	 by	 the	 loss	 and/or	 dysfunction	 of	 the	
endothelial	cells	leading	to	thrombosis	without	plaque	rupture.	Vasospasm	may	
be	involved	in	the	development	of	plaque	erosions.	
	 One	 of	 the	 most	 important	 factors	 leading	 to	 plaque	 rupture	 and	
consequent	 thrombosis	 is	 the	 thickness	 of	 the	 fibrous	 cap.	 Because	 thinner	
fibrous	caps	are	more	prone	to	rupture	the	term	thin-cap	fibroatheroma	(TCFA)	
was	 introduced,	 denoting	 the	 atherosclerotic	 plaques	with	 the	 highest	 risk	 for	
rupture.	 In	 fact,	 TCFAs	 are	 likely	 precursors	 of	 the	 majority	 of	 fatal	 coronary	
plaque	 ruptures	 (Falk	 et	al.,	 2013).	 Fibrous	 caps	 become	 thin	with	 the	 loss	 of	
smooth	muscle	cells	and	collagen,	which	is	potentiated	by	enzymes	secreted	by	
foam	cells,	such	as	proteases,	plasminogen	activators,	and	metalloproteinases.		
	 In	 summary,	 the	 plaques	 with	 the	 highest	 risk	 for	 rupture,	 the	
more	 vulnerable,	 or	 the	 most	 thrombosis-prone	 plaques	 are	 the	 ones	 with	 a	
large	acellular,	 lipid-rich	necrotic	 core	with	an	overlying	 fibrous	cap	 infiltrated	
by	inflammatory	cells	and	diffuse	calcification.	The	schematic	representation	of	









Figure	 7	 –	 Schematic	 representation	 of	 the	 proposed	 pro-atherogenic	
mechanism	of	Lp-PLA2	in	the	vessel	wall.	Lp-PLA2	binds	to	apoB	on	LDL,	which	
delivers	Lp-PLA2	 to	 lesion-prone	segments.	Subsequent	LDL	oxidation	 leads	 to	
formation	of	truncated	phospholipid	in	the	sn-2	position,	which	is	susceptible	to	
enzymatic	 hydrolysis	 by	 Lp-PLA2.	 This	 results	 in	 the	 generation	 of	
lysophosphatidylcholine	(lysoPC)	and	oxidized	nonesterified	fatty	acids	(NEFA),	
proinflammatory	mediators	that	are	also	cytotoxic	to	macrophages	and	facilitate	









individuals	 aged	 65-74	 years,	 and	 2,8-4,6%	 of	 patients	 >75	 years	 (Iung	 and	
Vahanian,	2014).	Pathophysiologically,	degenerative	calcific	aortic	stenosis,	 like	
atherosclerosis,	 represents	 an	 active,	 proliferative	 and	 inflammatory	 process	





patients	 die	 within	 2-3	 years.	 This	 makes	 early	 diagnosis	 and	 intervention	 of	
paramount	 importance.	 However,	 quite	 often,	 the	 diagnosis	 is	 made	 upon	 the	
development	 of	 symptoms,	 i.e.	 in	 an	 already	 advanced	 age,	 and	 in	 individuals	
otherwise	at	high	surgical	risk	due	to	other	concomitant	comorbidities.	In	these	
situations	 transcatheter	 aortic	 valve	 implantation	 (TAVI)	 is	 recommended	




left	 ventricle.	 Low-flow,	 low-gradient	 aortic	 stenosis	 with	 reduced	 ejection	
fraction	is	the	typical	phenotype	for	elderly	people	and	may	be	secondary	to	left	
ventricular	 systolic	 dysfunction	 or	 diminished	 ventricular	 volumes	 in	 a	
hypertrophied,	 stiffed	 left	 ventricle.	They	have	 the	worse	prognosis,	 even	after	
surgical	 aortic	 valve	 replacement	 (SAVR)	 or	 TAVI	 and,	 thus,	 require	 further	
investigations	 (e.g.	 distinguish	 between	 true	 and	 pseudo-stenosis)	 before	
choosing	the	adequate	treatment	modality.		
	 Currently,	 TAVI	 is	 only	 indicated	 in	 patients	 who	 are	 not	 suitable	 for	
SAVR.	 Nevertheless,	 recent	 clinical	 trials	 show	 a	 possible	 superiority	 over	
surgery,	 if	 the	 transfemoral	 (and	not	 the	apical)	 access	 is	used	 (Reardon	et	al.,	
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2017),	in	elderly	patients	and	even	in	adults	at	low	to	intermediate	risk	(Gargiulo	
et	al.,	 2016).	 The	main	 reasons	 for	 these	 positive	 results	 are	 the	 technological	
advancements	 in	 the	 prostethic	 valves	 aiming	 at	 reducing	 local	 complications	
such	 as	 paravalvular	 leaks,	 valve	 dislocation	 or	 embolization.		
	 Balloon	 valvuloplasty	 (BV)	 is	 used	 for	 palliation	 in	 patients	 in	 whom	
aortic	valve	replacement	cannot	be	performed	because	of	comorbid	conditions.	
It	can	also	be	used	as	a	bridge	to	SAVR	or	TAVI	in	unstable	patients.		Of	note,	the	
hemodynamic	 benefit	 of	 VA	 is	 only	 transient,	 lasting	 for	 only about 6 months	
(Ben-Dor	et	al.,	2013).	
	 In	 summary,	 the	 2017	 ESC/EACTS	 Guidelines	 for	 the	 management	 of	
valvular	heart	disease	(Baumgartner	et	al.,	2017)	recommend	SAVR	 in	patients	
at	low	surgical	risk	-	assessed	by	the	surgical	risk	calculator	from	the	Society	of	
Thoracic	 Surgeons	 or	 from	 the	 European	 System	 for	 Cardiac	 Operative	 Risk	























by	 an	 increase	 in	 plasma	 concentration	 of	 triglycerides	 (TG),	 decreased	
concentration	of	HDL	(HDL-C)	and	a	qualitative	change	in	the	LDL	fraction	due	to	
increased	 amounts	 of	 small	 and	 dense	 LDL	 (Arca,	 Pigna	 and	 Favoccia,	 2012).	
This	 triad	 can	 even	 be	 detected	 years	 before	 the	 diagnosis	 of	 type	 2	 diabetes	
mellitus	 (T2DM).	 There	 is	 increasing	 evidence	 that	 patients	 with	 T2DM	 have	




fatty	 acids	 from	 stored	 TGs.	 This	 means	 that	 insulin	 regulates	 the	 amount	 of	
circulating	fatty	acids	and	fails	to	inhibit	the	hormone	sensitive	lipase	in	states	of	
insulin	 resistance.	 The	 ensuing	 higher	 availability	 of	 free	 fatty	 acids	 leads	 to	 a	




rate	 of	 VLDL.	 Both,	 the	 overproduction	 and	 the	 decreased	 clearance	 of	 VLDL	
contribute	 for	 the	 hypertriglyceridemia	 seen	 in	 diabetic	 patients.	 Lipoprotein	
lipase	 is	 also	 inhibited	 by	 apoC-III.	 The	 expression	 of	 apoC-III	 is	 induced	 by	
glucose	and	inhibited	by	insulin.	Thus,	high	apoC-III	concentrations	prevent	the	
clearance	of	TG-rich	 lipoproteins	and	remnants,	resulting	 in	a	 further	elevation	
of	TGs.		
Not	only	due	to	the	features	described	above,	but	also	due	to	changes	in	
incretins	 secretion	 observed	 in	 states	 of	 insulin	 resistance,	 there	 will	 be	 an	
increase	 in	 postprandial	 TG-rich	 chylomicrons.	 These	 compete	 for	 the	 same	






HDL	 and	 LDL.	 TG-enriched	HDLs	 are	 subjected	 to	 increased	 catabolism,	which	
decreases	their	half-life	and,	thus	their	concentration.	Decreased	concentrations	
of	 HDL	 may	 result	 or	 exacerbate	 abnormal	 glucose	 homeostasis.	 TG-enriched	
LDLs	 are	hydrolyzed	by	 lipoprotein	 lipase	or	hepatic	 lipase,	which	 results	 in	 a	
reduction	of	 the	particle	size,	giving	rise	to	the	small	dense	LDLs	characteristic	
for	diabetic	dyslipidemia	(Wu	and	Parhofer,	2014).		
The	 small	 dense	 LDL	 particles	 are	more	 atherogenic	 than	 normal	 sized	
LDL.	They	are	more	prone	 to	be	removed	by	scavenger	receptors	and	 increase	




the	 total	 number	 of	 atherogenic	 lipoprotein	 particles	 since	 each	 LDL,	 VLDL,	
intermediate-density	lipoprotein	and	lipoprotein	(a)	contains	one	apoB.		
Because	Lp-PLA2	binds	preferentially	to	these	small	dense	LDL	particles,	
which	 are	 characteristic	 for	 DM,	 improving	 glycemic	 control	 may	 reduce	 Lp-
PLA2	activity.		It	has	been	estimated	that	the	amount	of	Lp-PLA2	in	small,	dense	
LDL	 or	 electronegative	 LDL	 is	 5	 to	 10	 times	 higher	 than	 in	 normal-sized	 LDL	
particles.	Furthermore,	the	fraction	of	Lp-PLA2	bound	to	HDL	is	reduced	(there	
is	 a	 relatively	 lower	 fraction	 of	 HDL	 particles	 in	 diabetic	 dyslipidemia)	 and	
improving	 glycemic	 control	 will	 increase	 the	 proportion	 of	 Lp-PLA2	 bound	 to	
HDL,	probably	potentiating	 its	atheroprotective	properties.	Finally,	 the	amount	
of	 lysophosphatidylcholine	 in	 circulation	 LDL	 is	 also	 increased	 in	 diabetic	
patients	 (Sonoki	et	al.,	 2009)	 and	 this	may	 be	 related	 to	 the	 increase	 Lp-PLA2	
activity.	
	 DM	per	se	increases	CVD	risk	two	to	four-fold	(Cho	et	al.,	2002).	This	risk	
is	 strongly	 determined	 by	 the	 presence	 of	 end-organ	 damage	 (including	
nephropathy,	 neuropathy	 and	 retinopathy).	 However,	 most	 of	 the	 times,	















We	 performed	 a	 cross-sectional	 analysis	 on	 44	 geriatric	 patients	 aged	
79.6	±	5.6	 years	 that	had	undergone	TAVI	or	ballon	valvuloplasty	 (BV)	 for	 the	
treatment	 of	 severe	 aortic	 stenosis.	 The	 patients	 were	 admitted	 to	 the	
Cardioangiologic	 clinic	 of	 the	 University	 Hospital	 of	 Hradec	 Králové,	 Czech	
Republic,	 between	 January	2009	and	 January	2011.	The	 subject	 characteristics	
are	 described	 on	 Table	 1.	 Most	 of	 the	 patients	 suffered	 from	 multiple	
comorbidities,	but	the	reason	for	admission	was	related	to	their	heart	problems.	
Two	of	them	had	a	BV	before	TAVI	(one	8	months	before	and	the	second	patient	
1	 month	 before);	 one	 of	 them	 needed	 BV	 3	 months	 after	 TAVI	 due	 to	 a	
































Plasma	 Lp-PLA2	mass	 concentrations	 were	 obtained	 using	 an	 enzyme-
linked	immunosorbent	assay	(ELISA)	kit	(Cloud-Clone	Copr.,	USA)	before	and	3	
days	 after	 the	 procedure.	 	 The	 recommended	 instructions	 from	 the	 producer	
were	 thoroughly	 followed.	 Intraassay	 variations	 were	 <10%,	 and	 interassay	
variations	 were	 <12%.	 The	 detection	 range	 of	 the	 assay	 was	 0.625-40ng/mL.	
Colored	 emission	 was	 then	 measured	 using	 the	 Multiskan	 Microplate	
Spectrophotometer	from	Thermofisher	Scientific.		
Succinctly,	a	specific	antibody	against	Lp-PLA2	is	applied	and	fixed	to	the	
internal	 side	of	 the	microtitre	wells.	The	blood	 sample	 is	 then	applied	and	Lp-
PLA2	binds	to	the	antibody.	After	washing	out	unbounded	components	from	the	
microtitre	 wells,	 a	 second	 antibody	 (labeled	 with	 biotin)	 against	 Lp-PLA2	 is	
added.	 A	 second	 washout	 follows	 before	 adding	 the	 enzyme	 horseradish	
peroxidase	labeled	with	avidin.	Avidin	reacts	with	the	biotin	forming	an	avidin-
biotin	 complex.	 After	 a	 third	 washout	 an	 indicator	 is	 added.	 The	 indicator	
changes	 color	 in	 the	 presence	 of	 horseradish	 peroxidade.	 The	 intensity	 of	 the	
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color	 is	 then	 proportional	 to	 the	 amount	 of	 the	 horseradish	 peroxidase	 in	 the	
complex,	 and	 consequently	 to	 the	 amount	 of	 Lp-PLA2	 in	 the	 sample.	 It	 is	
measured	 by	 a	 special	 photometer	 (an	 ELISA	 reader)	 and	 analyzed	 by	 an	
appropriate	 software,	which	evaluates	 the	 relation	between	 the	 color	emission	
and	 the	amount	of	Lp-PLA2	 in	 the	 sample	 in	 relation	 to	 a	 standard	 calibration	
samples.	
Fasting	blood	samples	were	obtained	immediately	before	and	then	3	days	
after	 the	 cardiac	 procedure	 from	 every	 patient.	 Blood	 was	 drawn	 and	
centrifuged	 immediately.	 The	 serum	 was	 then	 aliquoted	 and	 stored	 at	 -80°C.	
Total	cholesterol,	HDL-C	and	TGs	were	measured	by	enzymatic	methods;	LDL-C	
was	measured	by	routine	methods.		
For	 statistical	 analysis	 the	 open	 source	 software	 PSPP	 (Free	 Software	
Foundation,	Inc.,	USA)	was	used.	A	p-value	less	than	0.05	denoted	the	presence	




between	 2	 groups	 (diabetic	 and	 non-diabetic,	 TAVI	 and	 BV),	 independent	
(unpaired)	t-tests	were	used.		

















	 Concerning	 demographic	 and	 clinical	 characteristics	 at	 baseline,	 we	
examined	44	patients	aged	79.6	±	5.6	years	(average	age	±	standard	deviation).		
From	 those	 43.2%	 were	 males.	 Overall	 average	 BMI	 (calculated	 as	 the	 actual	
weight	 in	 kilograms	 divided	 by	 the	 squared	 height	 in	 meters)	 fell	 into	 the	
category	of	overweight	(27.6	±	4.7).	Measured	total	cholesterol	was	4.16	±	1.17	




















According	 to	 the	 2019	 ESC/EAS	 guidelines	 for	 the	 management	 of	
dyslipidemias,	 aortic	 valve	 sclerosis	 (calcification	 of	 the	 aortic	 leaflets	without	
significant	transvalvular	gradient)	is	associated	with	an	increased	risk	CAD	even	
in	 the	 absence	 of	 increased	 risk	 profiles.	 However,	 statin	 therapy	 in	 these	
patients	 failed	 to	 reduce	 the	 clinical	 progression	 of	 aortic	 stenosis,	 and	 a	
recommendation	against	the	initiation	of	lipid-lowering	therapy	in	patients	with	
aortic	 valve	 stenosis	 without	 CAD	 was	 issued.	 Even	 though	 the	 lipid	 profile	
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measured	in	our	study	may	be	considered	to	be	within	normal	range,	the	study	
population	 suffered	 from	 severe	 aortic	 stenosis,	 many	 of	 the	 patients	 had	
suffered	 a	 myocardial	 infarction	 in	 the	 past,	 had	 a	 medical	 history	 of	




mellitus	 and	 were	 either	 on	 insulin	 therapy	 (N=9),	 on	 peroral	 antidiabetics	
(N=3)	or	not	medicated	(N=9).		
The	 main	 objective	 of	 study	 was	 the	 assessment	 of	 Lp-PLA2	 mass	
concentration	 in	a	set	of	geriatric	patients.	However,	we	 followed	up	 the	study	
population	 during	 2	 years	 and	 we	 monitored	 for	 in-hospital	 periprocedural	
combined	 safety	 endpoints	 (i.e.	 all-cause	 mortality,	 major	 stroke,	 myocardial	




Lp-PLA2	 mass	 concentration	 was	 significantly	 correlated	 with	 relevant	
cardiovascular	 risk	 factors	 (as	 show	 in	 Table	 3).	 As	 predicted,	 a	 strong	
correlation	was	found	between	Lp-PLA2	mass	and	LDL-C	(coefficient	of	0.40,	P	=	
0.01)	as	LDL	particles	are	the	main	carrier	for	Lp-PLA2	(Figure	9).	However,	the	

































In	 the	present	 study,	 the	population	was	divided	 into	diabetic	 and	non-
diabetic	 patients	 to	 compare	 Lp-PLA2	mass	 concentration	 between	 them.	 The	
diagnosis	of	diabetes	mellitus	was	taken	from	the	available	medical	record.	We	
did	 not	 take	 into	 account	 whether	 diabetic	 patients	 were	 on	 diet,	 peroral	
antidiabetics	 or	 on	 insulin	 therapy.	 Using	 the	 independent	 samples	 t-test,	 we	
concluded	 that	 Lp-PLA2	 mass	 concentration	 is	 statistically	 significantly	
increased	(p=0.03)	in	the	diabetic	group	(1433.75	±	353.58	ng/ml)	comparing	to	




































diabetic	 and	 non-diabetic	 groups,	 meaning	 that	 the	 observed	 results	 after	 the	




apical	 or	 the	 transfemoral	 approach)	 or	BV.	Using	paired	 t-tests	we	 confirmed	
this	increment,	obtaining	a	statistically	significant	p<0.01	on	both	groups:	1)	for	
TAVI	1296	±	358	ng/mL	before	 the	procedure	and	1604	±	437	ng/mL	after	 it,	


























Using	 the	 independent	 samples	 t-test	 we	 noticed	 that	 Lp-PLA2	 mass	
concentrations	 before	 and	 after	 the	 intervention	 at	 the	 aortic	 valve	 do	 not	
change	differently	whether	TAVI	or	BV	was	performed.	We	obtained	a	p	value	of	
0.36	when	 comparing	 the	 2	 sets	 of	 patients	 before	 the	 respective	 intervention	
and	a	p	value	of	0.15	after	the	intervention.	This	observation	concludes	that	the	
enzyme	mass	concentration	significantly	increased	in	the	same	proportion	after	




concentration.	 Using	 independent	 samples	 t-tests,	 we	 conclude	 that	 the	 mass	










































	 In	 the	 past	 years,	 Lp-PLA2	 has	 been	 extensively	 studied	 as	 an	
independent	 risk	 factor	 for	CVDs	and	as	an	active	participant	 in	 the	process	of	
atherosclerotic	 plaque	 development.	 Data	 from	 more	 than	 50000	 patients	
revealed	 an	 association	 between	 increased	 Lp-PLA2	 activity	 or	 mass	






studies	 the	 normal	 range	 for	 Lp-PLA2	mass	 concentration	 for	men	was	 set	 at	
120-342	 ng/ml	 (90th	 percentile)(Colley,	 Wolfert	 and	 Cobble,	 2011).	 In	 our	
control	group	the	measured	average	Lp-PLA2	mass	concentration	was	788.23	±	
210.95	 ng/ml.	 This	 control	 group	 consisted	 of	 48	 healthy	 elderly	 individuals	
living	 at	 a	nursing	home.	We	assume	 that,	 even	 though	 these	 individuals	were	
categorized	 as	 “healthy”,	 they	were	 affected	 by	 subclinical	 atherosclerosis.	We	
emphasize	that,	in	real	practice,	when	studying	such	advanced	aged	individuals	it	
is	 almost	 impossible	 to	 find	completely	healthy	 subjects.	This	 terminology	was	
used	 to	 describe	 fully	 independent	 seniors	 able	 to	 walk	 without	 any	 aid	 or	
limitations,	and	without	cognitive	impairments.	
	 The	 study	 population	 consisted	 of	 elderly	 individuals	 that	 underwent	
catheter-based	 interventions	 at	 the	 aortic	 valve.	 TAVI	 and	 BV	 are	 procedures	
reserved	for	high-risk	patients	with	severe	aortic	stenosis.	From	this	premise	we	
can	 presume	 that	 the	 study	 population	 was	 affected	 by	 generalized	
atherosclerosis.	 This	 could	 explain	 the	 elevated	 Lp-PLA2	 mass	 concentrations	
(1319.77	 ±	 341.82	 ng/ml)	 measured	 in	 the	 study	 population	 before	 any	






	 Lp-PLA2	 mass	 concentrations	 measured	 before	 any	 intervention	 were	




total	 cholesterol	 has	 been	 established	 in	 several	 investigations	 (Tselepis	 and	







We	 did	 not	 find	 a	 correlation	 between	 Lp-PLA2	 and	 HDL-C.	 The	 first	
studies	in	mice,	rats	and	guinea	pigs	suggested	a	protective	function	for	Lp-PLA2.	
These	 species	 express	 lower	 concentrations	of	 LDL	and	Lp-PLA2	 is	 exclusively	
carried	 by	 HDL,	 conveying	 it	 antiatherosclerotic	 functions,	 for	 example	 by	 the	
inhibition	of	macrophage	infiltration	in	the	subendothelial	space	(Theilmeier	et	
al.,	 2000).	 We	 can	 assume	 that	 the	 reason	 why	 we	 did	 not	 find	 a	 correlation	
between	Lp-PLA2	and	HDL-C	is	connected	with	the	study	population,	a	high-risk	
group	 of	 patients	 with	 severe	 aortic	 stenosis	 and	 generalized	 atherosclerosis.	
Interestingly,	 N-linked	 glycosylation	 of	 plasma	 Lp-PLA2	 hinders	 its	 binding	 to	
HDL	(Tselepis	et	al.,	2001),	meaning	that	the	removal	of	glycosylation	enhances	
its	 association	 with	 HDL.	 This	 could	 be	 explored	 in	 the	 future	 for	 new	
pharmacological	interventions.		
	 Three	 days	 after	 the	 intervention	 on	 the	 aortic	 valve	 (TAVI	 or	 BV)	 we	
measured	the	Lp-PLA2	mass	concentration	in	all	44	elderly	patients	included	in	
the	 study.	 The	 results	 showed	 a	 significant	 increase	 in	 the	 enzyme	 mass	
concentration.		Because	the	pathophysiology	processes	for	aortic	calcific	stenosis	
and	 atherosclerosis	 are	 the	 same,	 we	 can	 speculate	 a	 higher	 amount	 of	 this	




the	 procedure	 or	 due	 to	 other	 unknown	 processes	 is	 just	 pure	 speculation	
because	 this	 biomarker	 was	 not	 tested	 before	 in	 this	 setting	 (in	 patients	
undergoing	TAVI	or	BV).	The	impact	of	these	results	is	not	known,	but	it	could	be	
considered	during	the	follow-up	of	these	high-risk	patients.		
	 Finally,	 we	 divided	 the	 study	 population	 in	 two	 groups	 concerning	 the	
presence	 or	 absence	 of	 diabetes	 mellitus	 in	 their	 medical	 history.	 For	 further	
statistical	analysis	we	did	not	take	into	account	the	type	of	diabetic	control	used	
by	 these	 patients.	 42%	 of	 them	 were	 on	 a	 diabetic	 diet,	 14%	 on	 peroral	
antidiabetics	 and	 42%	 on	 insulin	 therapy.	 However,	 the	 results	 of	 our	 study	
showed	 a	 statistically	 significant	 higher	 Lp-PLA2	 mass	 concentration	 on	
admission	 in	 diabetic	 patients	 when	 comparing	 to	 individuals	 without	 this	
disease.	 These	 results	 are	 in	 agreement	 with	 other	 previous	 studies	 (Noto,	
Chitkara	 and	 Raskin,	 2006;	 Corsetti	 et	 al.,	 2007).	 We	 did	 not	 find	 other	
statistically	 significant	 differences	 between	 diabetic	 and	 non-diabetic	 patients,	
including	no	differences	in	LDL-C,	HDL-C	and	TG.	This	can	partly	be	explained	by	
the	 fact	 that	 62%	 of	 diabetic	 and	 most	 of	 non-diabetic	 patients	 were	 being	
treated	 with	 a	 statin	 at	 the	 time	 of	 the	 study.	 It	 has	 been	 demonstrated	 that	
statins	 reduce	 the	activity	of	Lp-PLA2	 in	patients	with	diabetes	 (Winkler	et	al.,	
2004).	
	 As	described	in	the	background	section,	diabetic	patients	exhibit	a	typical	
set	 of	 lipid	 abnormalities	 (often	 termed	 diabetic	 dyslipidemia),	 consisting	 of	
increased	 TG	 concentration,	 decreased	 HDL-C	 and	 a	 qualitative	 change	 in	 the	
LDL	fraction	towards	smaller	and	denser	particles.	These	particles	can	be	easily	
taken	up	by	macrophages	 in	extravascular	spaces	contributing	and	resulting	 in	
atherogenesis.	 Furthermore,	Lp-PLA2	binds	preferentially	 to	 these	 small	dense	
LDL	particles,	which	 can	explain	 the	abnormal	distribution	of	Lp-PLA2	 (with	a	
relatively	lower	fraction	in	HDL	particles),	 in	diabetes	mellitus	(Kujiraoka	et	al.,	
2006).	 Improving	 glycemic	 control	 may	 reduce	 Lp-PLA2	 activity,	 mainly	 by	
increasing	 the	 relative	 proportion	 of	 Lp-PLA2	 bound	 to	 HDL,	 which	 has	 been	
suggested	 to	 be	 atheroprotective	 (Sánchez-Quesada	 et	 al.,	 2012).	 It	 has	 been	





may	be	 related	 to	 the	 increased	Lp-PLA2	activity.	A	prospective	 study	 showed	
that	 higher	 levels	 of	 Lp-PLA2	 activity	 were	 associated	 with	 increased	 risk	 of	
incident	 coronary	heart	disease	among	diabetic	 subjects	 (Hatoum	et	al.,	 2010).	
However,	a	 comparison	between	diabetic	and	non-diabetic	 individuals	was	not	
made.		




TG	 concentrations.	 In	 states	 of	 insulin	 resistance,	 insulin	 fails	 to	 inhibit	 the	
hormone	sensitive	lipase,	leading	to	the	mobilization	of	free	fatty	acids	from	the	
adipose	tissue.	These	may	impair	the	activity	of	lipoprotein	lipase	and	lead	to	a	
decrease	 in	 the	 catabolism	 of	 triglyceride-rich	 apoB	 lipoproteins,	 causing	 an	
overproduction	 of	 VLDL.	 Low	 concentrations	 of	 Lp-PLA2	 can	 bind	 to	 VLDL	
(Srinivasan	 and	 Bahnson,	 2010),	 the	 main	 carrier	 of	 TG	 into	 the	 tissues.	 This	
could	 explain	 the	 positive	 correlation	 between	 Lp-PLA2	 mass	 and	 TG	
concentrations	found	in	this	study.		
	 Of	 note,	 elevated	 LDL-C,	 elevated	 TG	 concentrations	 and	 low	 levels	 of	
HDL-C	 are	 strongly	 associated	 with	 increased	 risk	 for	 macrovascular	 (e.g.	
myocardial	 infarction,	 ischemic	 stroke,	 and	 coronary	 mortality)	 and	
microvascular	(retinopathy,	neuropathy,	and	nephropathy)	among	patients	with	
T2DM	(Toth	et	al.,	2012).		
	 Levels	 of	measured	 Lp-PLA2	mass	 concentration	 in	 this	 population	 are	
extremely	 elevated	 compared	 with	 other	 studies.	 Pre-analytical	 and	 analytical	
errors	 are	 a	 main	 concern.	 The	 temperature	 of	 the	 samples	 may	 induce	
biochemical	 coupling	 and	 uncoupling	 of	 Lp-PLA2	 to	 the	 binding	molecule	 (for	
example	LDL).	Because	of	this	process,	it	is	recommended	that	samples	undergo	
immediate	 separation	 and	 freezing	 at	 -70	 degrees	 Celsius	 for	 at	 least	 18-24h	
prior	to	analysis.	They	should	then	be	thawed	to	4	degrees	Celsius	prior	to	the	
assay	(Oliver	et	al.,	2011).	In	our	study	blood	samples	were	drawn	from	patients	
to	 serum	 clot	 sample	 tubes	 and	 immediately	 centrifuged	 upon	 arrival	 at	 the	
same	 hospital	 laboratory.	 The	 serum	 was	 then	 aliquoted	 and	 stored	 at	 -80	
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degrees	 Celsius.	 Due	 to	 logistic	 and	 financial	 issues	 the	 samples	 were	 then	
thawed	to	4	degrees	Celsius	and	examined	by	the	ELISA	assay	once	there	was	a	
significant	number	of	samples	to	be	analyzed.	We	cannot	prove	if	this	approach	
influenced	 the	 results	 of	 our	 analysis,	 even	 though	 it	 is	 the	 standard	
methodology	of	our	and	most	of	other	laboratories.	 
	 The	 same	 methodology	 was	 used	 to	 measure	 Lp-PLA2	 mass	
concentration	 in	 the	 control	 group.	 This	 reduces	 the	 eventual	 pre-analytical	
problem	described	in	the	previous	paragraph.		
	 Another	 possible	 explanation	 for	 our	 results	 is	 related	 to	 the	 lithium-
heparin	sample	tubes.	This	type	of	preservative	can	alter	the	results	of	Lp-PLA2 
mass	concentration,	resulting	in	higher	measured	values	by	ELISA.			
	 In	 addition,	 the	 results	 of	 commercially	 available	 assays	 for	 the	
measurement	 of	 Lp-PLA2	 mass	 concentration,	 the	 PLAC	 assays	 are	 often	 not	
enough	 reproducible	 for	 statistical	 purposes.	 It	 has	 been	 suggested,	 that	
measures	 of	 Lp-PLA2	 activity	might	 serve	 as	 a	more	 representative	marker	 of	
the	enzyme	function.	
From	the	studied	literature	there	are	some	postulations	worth	mentioning.		
The	vast	 available	 studies	 tried	 to	 find	 correlations	between	Lp-PLA2	mass	
concentration	 and	 activity	 with	 cardiovascular	 events.	 Meaning	 that,	 most	 of	
them	are	epidemiological	studies.	Most	found	a	positive	correlation	between	Lp-
PLA2	and	 cardiovascular	diseases,	 but	 some	did	not.	As	mentioned	earlier,	 the	
oxidation	 of	 LDL	 particles	 is	 one	 of	 the	 first	 steps	 in	 the	 pathogenesis	 of	
atherosclerosis.	With	an	 increase	 in	oxidized	LDL	the	 innate	 immune	system	 is	
activated	and	mobilizes	monocytes	and	macrophages	to	the	arterial	wall.	At	this	
stage	 the	 amount	 of	 Lp-PLA2	 rises	 exponentially	 and	 targets	
glycerophospholipids	containing	short	and/or	oxidized	functionalities	at	the	sn-2	
position,	 generating	 lysophosphatidylcholine	 and	 NEFAs,	 which	 have	 been	
reported	 to	 have	proinflammatory	 and	pro-oxidative	 activities.	 The	hypothesis	
that	 Lp-PLA2	might	 actively	 contribute	 to	 inflammation	 during	 atherosclerosis	
led	 to	 the	 development	 of	 reversible	 inhibitors.	Of	which,	 darapladib	 has	 been	
extensively	 tested	 and	 failed	 to	 reduce	 the	 incidence	 of	 cardiovascular	 death,	
myocardial	 infarction,	stroke	or	all-cause	mortality	 in	patients	with	stable	CVD,	
and	 failed	 to	 reduce	 the	 incidence	 of	 major	 coronary	 events	 after	 an	 acute	
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coronary	 syndrome.	 These	 findings	 raise	 the	 question	 whether	 the	 elevated	
enzyme	 levels	 might	 reflect	 a	 response	 to	 the	 proinflammatory/pro-oxidative	
stress	that	is	typical	for	atherosclerosis	(Stafforini	and	Zimmerman,	2014).		
Furthermore,	 the	 strong	 positive	 correlation	 of	 Lp-PLA2	 with	 LDL-C	
demonstrates	 that	 elevated	 circulating	 levels	 of	 Lp-PLA2	 is	 associated	 with	
atherosclerosis,	but	such	observations	do	not	show	a	causal	role	for	Lp-PLA2	in	
the	disease	process.		
Another	 key	 unanswered	 question	 is	 whether	 Lp-PLA2	 functions	 in	 the	
circulation,	 in	 atherosclerotic	 plaques	 and	 other	 tissues,	 or	 both.	 Transport	 to	



























2) Lp-PLA2	mass	 concentration	 is	 increased	 in	 elderly	patients	with	 aortic	




4) A	statistically	significant	 increase	 in	Lp-PLA2	mass	concentration	occurs	
after	TAVI	or	BV.	
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